3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
2
Glioblastoma
2
Stroke
1
Recurrence
1
Ovarian Neoplasms
1
Neurologic Manifestations
1
Melanoma
1
Margins of Excision
1
Malignant Solid Neoplasm
1
Malignant Female Reproductive System Neoplasm
1
Localized Head and Neck Carcinoma
1
Inflammatory Breast Neoplasms
1
Fallopian Tube Neoplasms
1
Communication
1
Colorectal Neoplasms
1
Caregiver Burden
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Brain Neoplasms
1
Brain Injuries, Traumatic
1
Brain Injuries
1
Advanced Malignant Solid Neoplasm
1
Interventions
Cyclophosphamide
3
fludarabine
2
Paclitaxel
2
Carboplatin
2
Bevacizumab
2
trastuzumab deruxtecan
1
pembrolizumab
1
olaparib
1
niraparib
1
mirvetuximab soravtansine
1
irinotecan sucrosofate
1
fludarabine phosphate
1
denileukin diftitox
1
Tinzaparin
1
Propranolol
1
Palliative Care
1
Nivolumab
1
Neoadjuvant Therapy
1
Music Therapy
1
Losartan
1
Indocyanine Green
1
GEN-1
1
Etodolac
1
E7777 fusion protein
1
Clarithromycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
Palliative Care
×
30 days
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled